The objective of this paper is to review the safety of doxazosin in older patients ( ! 65 y) with benign prostatic hyperplasia (BPH) as reported in seven international clinical trials. Data from seven double-blind, placebo-controlled, phase III trials, in both normotensive and hypertensive patients with BPH were collated and analysed. Data on doxazosin were available for 341 men 65 y and over. Even though older patients can be at particular risk of adverse drug reactions, there was no apparent evidence of poor tolerability with doxazosin in older patients with BPH. The percentages of younger normotensive BPH patients (`65 y) experiencing at least one adverse event were 47 and 44% for doxazosin and placebo groups, respectively; for older normotensive BPH patients ( ! 65 y) the corresponding values were 42 and 38%. For the younger hypertensive BPH patients the incidence rates for adverse events were 55% (doxazosin) and 42% (placebo) and for older hypertensive BPH patients 43 and 30%, respectively. The most commonly reported adverse events for all groups were dizziness, headache and fatigue and few serious adverse effects were reported throughout these trials. It can be concluded that doxazosin is well tolerated in young and old, normotensive and hypertensive patients with BPH.
Introduction
The prevalence of benign prostatic hyperplasia (BPH) increases with advancing age and it represents a widespread disorder in the elderly. Actual prevalence rates vary according to the population studied and the de®ni-tion of BPH used. For example, a population survey in Minnesota showed that 13% of men aged 40±49 y and 28% of men over 70 y had moderate-to-severe obstructive symptoms;
1 while in a Scottish population survey higher prevalence rates of 14 and 43% for men in the ®fth and seventh decades, respectively, were found using a de®ni-tion of BPH based on the size of the prostate. 2 In addition, pooled results of several autopsy studies indicated that the numbers of men with BPH (meeting histological criteria) rises with age, with 88% of men aged over 80 y having histological disease. 3 Hypertension is also a common age-related disorder. It is estimated that at least one eighth of all men over 60 y of age will acquire both symptomatic BPH and hypertension. 4 Moreover, a recent Portuguese community-based study found that men with severe BPH (an International Prostate Symptom Score, I-PSS of ! 20) had a signi®-cantly increased risk of hypertension compared with men who had less severe symptoms, I-PSS 7. 5 While further studies are needed to verify these ®ndings, it is possible that there is an association between BPH and hypertension. Indeed, the alpha-1 adrenoceptor is involved in modulating smooth muscle tone in both the lower urinary tract and the vasculature. Doxazosin, a selective alpha-1 adrenergic antagonist, has proven ef®cacy in patients with BPH.
6±11 It is also a well established ®rst-line treatment option in essential hypertension 12 and is included in the guidelines of both the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure 13 and the World Health OrganisationaInternational Society of Hypertension 14 for the treatment of hypertension. Doxazosin may, therefore, be useful where these diseases coexist.
Many of the patients with BPH, hypertension or both, are likely to be over 65 y of age. This age group is particularly susceptible to adverse drug reactions, due both to the physiological changes of ageing and the frequent necessity for multiple drug therapy. It is, therefore, important that the safety and tolerability of a drug which could be used widely in older patients is thoroughly evaluated in this population.
This review will summarise and assess the data on the safety of doxazosin in patients above and below 65 y of age, obtained during seven phase III trials, in both normotensive and hypertensive patients with BPH.
Methods
Safety data were collected on normotensive and hypertensive BPH patients enrolled in seven multicentre, double-blind, placebo-controlled, parallel group, phase III trials on doxazosin (conducted in Europe, Canada and the US). Normotensive patients (de®ned as normotensives or pharmacologically-controlled hypertensives with a sitting diastolic blood pressure 90 mmHg) were included in six of these trials, 6±10 four of which also enrolled subjects with untreated mild-to-moderate hypertension. 7 A further phase III study only recruited uncontrolled hypertensives with BPH.
11
Patients with symptomatic BPH and no history of serious concurrent disease, signi®cant cardiovascular, hepatic or renal dysfunction, were eligible for these studies. Patients entered a placebo run-in phase which lasted for at least one week (Table 1 ) and were then randomised to double-blind treatment with doxazosin or placebo for 4±29 weeks. The proportion of patients randomised to doxazosin varied between trials, but overall, approximately twice as many patients received doxazosin as placebo ( Table 1 ). The initial dose of doxazosin was 1 mgad, which in the majority of patients was then sequentially titrated upward every 1±2 weeks to the maximally effectiveatolerated dose (generally 1±4 mgad, but up to 16 mgad in some patients) ( Table 1 ). All observed and reported adverse events, whether considered to be treatment-related or not, were recorded at regular intervals throughout the trials. In addition, reports of orthostatic events were collected and the 
Results

Normotensive BPH patients
A total of 635 normotensive BPH patients enrolled in the phase III trials. Three hundred and twenty (50%) were aged 65 y and over and of these, 217 received doxazosin. The incidence of adverse events for normotensive BPH patients receiving doxazosin was similar to those receiving placebo, whether younger or older than 65 y of age (Table 2a) . Generally, events did not occur more frequently in the older age group compared with the younger patients (Table 2a) . If anything, the incidences of adverse events for doxazosin and placebo-treated patients were slightly lower for the older patients.
The majority of adverse events with doxazosin and placebo were mild to moderate in severity for both younger and older patients. Withdrawal rates due to adverse experiences were similar in older and younger patients, regardless of whether they received doxazosin or placebo (Table 2a) .
The most common adverse events (incidence ! 5%) were dizziness, headache and fatigue ( Figure 1) . Each occurred at a similar frequency in both age groups of the doxazosin-treated patients. Compared with placebo, only slight increases in the rates of adverse events (for example fatigue) were observed in the doxazosin-treated elderly normotensives. Postural hypotension and other cardiovascular events (chest pain, palpitation, angina pectoris, myocardial infarction, syncope, tachycardia and bradycardia) were rare (incidence of 1%).
No clear trend between overall frequency of adverse events and doxazosin dosage emerged in normotensives in either age group. Only the incidences of dizziness and headache were slightly higher at 8 mgad than at the lower doses in the younger group (Table 3) .
In normotensive patients treated with doxazosin, only a small reduction in mean systolic and diastolic blood pressure was seen. These changes, which were not clinically signi®cant, were similar in older and younger groups of patients (Table 4) .
There were no clinically signi®cant changes in heart rate in any of the treatment groups. The incidence of Figure 1 Most common adverse events ( ! 5%) reported in younger (`65 y) and older ( ! 65 y) normotensive patients with BPH. Doxazosin: safety in the elderly R Kirby and A Jardin treatment-emergent ECG abnormalities was similar in the doxazosin and placebo groups in both younger (n 183) and older (n 138) normotensive patients. The most frequent abnormality was sinus bradycardia, which occurred in a similar proportion of patients in each ageatreatment group.
Hypertensive BPH patients
The number of BPH patients with previously uncontrolled hypertension enrolled in these trials was 326. One hundred and seventy (52%) were 65 y and over, of whom 124 received doxazosin. The overall incidence and the most commonly reported adverse events (incidence ! 5%) experienced in these hypertensive BPH patients are presented in Table 2b and Figure 2 . For each age group, compared with the placebo-treated patients, slightly more doxazosin-treated patients experienced at least one adverse event and withdrew from therapy because of adverse events (Table 2b) .
Comparing the data in Tables 2a and 2b , and Figures 1  and 2 , it is apparent that, overall, doxazosin was slightly better tolerated in normotensives than in hypertensives, in both age groups. However, as with normotensives, very few hypertensive men experienced serious adverse events.
Discussion
Generally, elderly patients are at increased risk of adverse drug reactions compared with younger patients. This Figure 2 Most common adverse events ( ! 5%) reported in younger (`65 y) and older ( ! 65 y) hypertensive patients with BPH.
Doxazosin: safety in the elderly R Kirby and A Jardin may be due to altered drug metabolism and the frequent need for polypharmacy. In the phase III studies reported here, including 341 doxazosin-treated BPH patients over the age of 65 y, with and without concomitant hypertension, the drug was found to be well tolerated in the elderly. Moreover, these studies indicated a similar, and possibly slightly better, toleration of doxazosin by elderly normotensive BPH patients compared with younger normotensive BPH patients. These ®ndings in BPH patients support the data from controlled hypertension trials 15 and general practice studies 16 which indicate that the incidence and pro®le of adverse events in older patients is similar to the study population as a whole. Generally, the safety pro®le of doxazosin in BPH is comparable with that in hypertensive patients. 12 In the phase III trials, a trend between frequency of adverse events and dosage (0.5±16 mg) was not apparent in either age group. This could be important since the ef®cacy of doxazosin (for example effect on symptoms or ow rate) is dose-related 7, 10, 11 and the dose often has to be titrated upward to establish maximum ef®cacy.
As both hypertension and BPH can progress over a number of years, treatment usually needs to be long-term, and so good toleration and patient compliance should ideally be maintained. Data from long-term open studies of doxazosin in both hypertension 17 and BPH 18, 19 indicate that doxazosin appears to be well tolerated in the longterm. Interim analysis of ongoing open-label extensions (up to 42 months) of these double-blind phase III studies, in which 450 patients with BPH with or without concomitant hypertension entered, has revealed no clear differences in the toleration pro®le of doxazosin between younger and older patients, whether hypertensive or normotensive. 18, 19 As in the original phase III studies, most adverse events were not serious and the most commonly reported continue to be dizziness, headache and fatigue, none of which have occurred more frequently in older than younger men. Likewise, events related to the cardiovascular system, including syncope, have rarely occurred in either age group.
In the phase III trials, doxazosin only slightly decreased the mean blood pressure of normotensive patients with BPH, irrespective of age. While reductions in blood pressure were encountered in a proportion of patients treated with doxazosin, similar experiences occurred in the placebo groups, and the reductions were not deemed to be clinically signi®cant. It has also been reported that doxazosin fails to produce a clinically signi®cant reduction in blood pressure of`pharmacologically normotensive' BPH patients (that is those with hypertension controlled by antihypertensive therapy 20 ) or iǹ white coat hypertensives' (patients whose ambulatory blood pressure is normal, but who have a raised blood pressure in the clinic). 21 The apparent paradox between these observations and the clinical ef®cacy of doxazosin in reducing blood pressure in hypertensive patients may be explained by the observation that doxazosin attenuates pathologically raised, but not normal, peripheral vascular resistance. 22 The implications of this for clinical practice could mean that if doxazosin is given to normotensive patients with BPH, including those well-controlled by other antihypertensives, concern of an adverse hypotensive effect may be reduced.
First-dose effects, such as hypotension, syncope and other postural effects, have been associated with alphablocker therapy, 23 but largely with shorter acting agents, such as prazosin, and were extremely rare during these studies. Doxazosin, as a result of its long duration of action (half life is 22 h) and gradual onset of action (time to peak concentration 2±4 h), 12 may produce fewer orthostatic effects than other currently available alpha blockers. Any postural effects can usually be avoided by careful dose titration from an initial 1 mg dose of doxazosin. With respect to the half life of doxazosin, this has been found to be similar in older and younger hypertensive patients 24 and volunteers. 12 
Conclusions
Given the large and increasing numbers of men over the age of 65 y with BPH, any data demonstrating that treatment is well tolerated in this age group should be welcomed. Doxazosin, for example, appears to be well tolerated in both young and old, normotensive and hypertensive patients with BPH. In addition, the kinetic and dynamic pro®le of doxazosin makes it suitable for once-daily administration, at any time of the day or evening, which could be considered a desirable feature in elderly patients as it minimises the chances of noncompliance.
